Published in Oncogene on September 27, 2001
Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2006) 5.08
Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev (2003) 2.32
Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages. J Biol Chem (2010) 1.70
(R)-beta,gamma-fluoromethylene-dGTP-DNA ternary complex with DNA polymerase beta. J Am Chem Soc (2007) 1.48
Protective role of Puralpha to cisplatin. Cancer Biol Ther (2008) 1.44
Halogenated beta,gamma-methylene- and ethylidene-dGTP-DNA ternary complexes with DNA polymerase beta: structural evidence for stereospecific binding of the fluoromethylene analogues. J Am Chem Soc (2010) 1.21
Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide. Mol Pharmacol (2008) 1.18
Aag-initiated base excision repair drives alkylation-induced retinal degeneration in mice. Proc Natl Acad Sci U S A (2009) 1.09
Novel role of base excision repair in mediating cisplatin cytotoxicity. J Biol Chem (2011) 1.04
The roles of DNA polymerase ζ and the Y family DNA polymerases in promoting or preventing genome instability. Mutat Res (2012) 0.99
Structural insight into dynamic bypass of the major cisplatin-DNA adduct by Y-family polymerase Dpo4. EMBO J (2010) 0.98
Hairpin structure within the 3'UTR of DNA polymerase beta mRNA acts as a post-transcriptional regulatory element and interacts with Hax-1. Nucleic Acids Res (2007) 0.93
HAX-1 promotes the chemoresistance, invasion, and tumorigenicity of esophageal squamous carcinoma cells. Dig Dis Sci (2012) 0.92
DNA polymerase beta overexpression stimulates the Rad51-dependent homologous recombination in mammalian cells. Nucleic Acids Res (2004) 0.89
Gastrointestinal hyperplasia with altered expression of DNA polymerase beta. PLoS One (2009) 0.83
RNA aptamers selected against DNA polymerase beta inhibit the polymerase activities of DNA polymerases beta and kappa. Nucleic Acids Res (2006) 0.82
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. Oncotarget (2015) 0.81
Structural basis for the inefficient nucleotide incorporation opposite cisplatin-DNA lesion by human DNA polymerase β. J Biol Chem (2014) 0.80
Two Scaffolds from Two Flips: (α,β)/(β,γ) CH2/NH "Met-Im" Analogues of dTTP. Org Lett (2015) 0.80
An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells. PLoS One (2013) 0.79
Structural insights on the pamoic acid and the 8 kDa domain of DNA polymerase beta complex: towards the design of higher-affinity inhibitors. BMC Struct Biol (2008) 0.77
Involvement of DNA polymerase β overexpression in the malignant transformation induced by benzo[a]pyrene. Toxicology (2013) 0.76
Gut Microbiota Imbalance and Base Excision Repair Dynamics in Colon Cancer. J Cancer (2016) 0.76
DNA polymerase beta germline variant confers cellular response to cisplatin therapy. Mol Cancer Res (2017) 0.75
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res (1998) 2.63
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res (1999) 2.50
The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (1990) 2.43
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol (1999) 2.29
Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer (1993) 2.10
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 1.88
Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells. Eur J Cancer Clin Oncol (1989) 1.68
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst (1997) 1.58
cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res (1988) 1.56
Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia. Leukemia (2005) 1.53
Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol (1993) 1.52
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res (1997) 1.50
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res (1997) 1.47
Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med (1982) 1.46
Circulating immunoglobulin complexes in Wegener's granulomatosis. Am J Med (1976) 1.43
Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol (1992) 1.39
A 'DNA replication' signature of progression and negative outcome in colorectal cancer. Oncogene (2009) 1.33
The p400/Tip60 ratio is critical for colorectal cancer cell proliferation through DNA damage response pathways. Oncogene (2009) 1.30
Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res (1985) 1.30
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res (1997) 1.29
Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol (2001) 1.28
Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun (1990) 1.27
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer (2001) 1.26
Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer (1994) 1.26
Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. Proc Natl Acad Sci U S A (1998) 1.24
Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol (1996) 1.23
Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res (1983) 1.23
Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck (1992) 1.22
Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck (2000) 1.21
Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer (1991) 1.18
Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol (1993) 1.16
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res (1987) 1.16
Totally implantable system for peritoneal access. J Clin Oncol (1984) 1.15
Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett (1998) 1.15
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol (1987) 1.13
Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res (2000) 1.13
Mutagenicity and pausing of HIV reverse transcriptase during HIV plus-strand DNA synthesis. Nucleic Acids Res (1994) 1.13
Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol (1994) 1.11
Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem (1990) 1.10
Role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol (1994) 1.10
Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol (1999) 1.08
Defects in cell-mediated immunity during growth of a syngeneic simian virus-induced tumor. Int J Cancer (1975) 1.07
In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery. Gene Ther (2007) 1.06
Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153. Br J Cancer (1996) 1.06
The UL8 subunit of the herpes simplex virus type-1 DNA helicase-primase optimizes utilization of DNA templates covered by the homologous single-strand DNA-binding protein ICP8. J Biol Chem (1996) 1.06
Homologous and heterologous desensitization of a guanylyl cyclase-linked nitric oxide receptor in cultured rat medullary interstitial cells. J Pharmacol Exp Ther (1994) 1.05
Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest (1990) 1.03
Biochemical characterization of the human arsenite-stimulated ATPase (hASNA-I). J Biol Chem (1998) 1.03
Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer (1999) 1.03
Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol (1990) 1.01
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br J Cancer (1998) 1.00
DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients. Oncogenesis (2012) 1.00
Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur J Cancer (2004) 1.00
TNF-alpha and IFN-gamma induce expression of nitric oxide synthase in cultured rat medullary interstitial cells. Am J Physiol (1995) 1.00
Cell interactions in adoptive immune rejection of a syngeneic tumor. Int J Cancer (1974) 0.99
Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol (1996) 0.98
Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res (2001) 0.98
Induction of the growth arrest and DNA damage-inducible gene GADD153 by cisplatin in vitro and in vivo. Br J Cancer (1994) 0.98
Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res (1993) 0.98
Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer (2008) 0.97
Yeast mutants as a model system for identification of determinants of chemosensitivity. Pharmacol Rev (2000) 0.97
Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem Biol Interact (1988) 0.97
P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res (2001) 0.97
Adaptation to DNA damage and stimulation of genetic instability: the double-edged sword mammalian DNA polymerase kappa. Biochimie (2005) 0.96
Overexpression of DNA polymerase beta: a genomic instability enhancer process. FASEB J (1999) 0.96
Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer. Oncogene (2006) 0.95
Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity. Cancer Res (1981) 0.95
Localization and regulation of endothelial NO synthase mRNA expression in rat kidney. Am J Physiol (1994) 0.95
Thymidine requirements for the rescue of patients treated with high-dose methotrexate. Cancer Res (1980) 0.94
Methotrexate pharmacokinetics after intraarticular injection in patients with rheumatoid arthritis. Arthritis Rheum (1980) 0.93
Mutator phenotype of BCR--ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene (1999) 0.93
Nucleotide excision repair DNA synthesis by excess DNA polymerase beta: a potential source of genetic instability in cancer cells. FASEB J (2000) 0.93
Cellular immunity in mice with simian virus 40-induced mKSA tumors: comparison of three assays of tumor immunity. J Natl Cancer Inst (1974) 0.93
In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest (1993) 0.93
Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J Clin Oncol (1984) 0.93
New mutations in and around the L2 disordered loop of the RecA protein modulate recombination and/or coprotease activity. J Bacteriol (1992) 0.93
Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. J Clin Oncol (1993) 0.92
Novel evidences for a tumor suppressor role of Rev3, the catalytic subunit of Pol zeta. Oncogene (2008) 0.92
Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells. J Clin Invest (1995) 0.92
Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res (1992) 0.92
Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer (1997) 0.92
Identification of genes differentially expressed in association with acquired cisplatin resistance. Br J Cancer (2000) 0.92
RAD51 supports spontaneous non-homologous recombination in mammalian cells, but not the corresponding process induced by topoisomerase inhibitors. Nucleic Acids Res (2001) 0.92
Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity. J Clin Oncol (1985) 0.92
Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer (1998) 0.91
Modulation of cellular response to cisplatin by a novel inhibitor of DNA polymerase beta. Mol Pharmacol (2005) 0.91
Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br J Cancer (1994) 0.91